Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response

Vardiman, 2008, 18 Tefferi, 2008, Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, 22, 14, 10.1038/sj.leu.2404955 Pozdnyakova, 2015, Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms, Clin Lymphoma Myeloma Leuk, 15, 253, 10.1016/j.clml.2014.11.002 Mascarenhas, 2013, Advances in myelofibrosis: a clinical case approach, Haematologica, 98, 1499, 10.3324/haematol.2013.086348 Levine, 2007, Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders, Nat Rev Cancer, 7, 673, 10.1038/nrc2210 Nangalia, 2013, Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2, N Engl J Med, 369, 2391, 10.1056/NEJMoa1312542 Cervantes, 2009, New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, 113, 2895, 10.1182/blood-2008-07-170449 Cervantes, 2012, Improving survival trends in primary myelofibrosis: an international study, J Clin Oncol, 30, 2981, 10.1200/JCO.2012.42.0240 Cervantes, 2014, How I treat myelofibrosis, Blood, 124, 2635, 10.1182/blood-2014-07-575373 Passamonti, 2014, Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts, Blood, 123, 1833, 10.1182/blood-2013-12-544411 Wang, 2014, JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis, Blood, 124, 2987, 10.1182/blood-2014-02-558015 Cervantes, 2013, Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis, Blood, 122, 4047, 10.1182/blood-2013-02-485888 Silver, 2013, Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis, Expert Rev Hematol, 6, 49, 10.1586/ehm.12.69 Quintas-Cardama, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a, Blood, 122, 893, 10.1182/blood-2012-07-442012 Silver, 2011, Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report, Blood, 117, 6669, 10.1182/blood-2010-11-320069 Silver, 2009, Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis, Leukemia, 23, 1366, 10.1038/leu.2009.90 Ianotto, 2013, Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups, Br J Haematol, 162, 783, 10.1111/bjh.12459 Stauffer Larsen, 2013, Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha, Leuk Res, 37, 1041, 10.1016/j.leukres.2013.06.012 Nguyen, 2012, Is there a role for the use of IFN-α in primary myelofibrosis?, Hematol Am Soc Hematol Educ Program, 2012, 567, 10.1182/asheducation.V2012.1.567.3806899 Tefferi, 2013, International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report, Blood, 122, 1395, 10.1182/blood-2013-03-488098 Geyer, 2014, Therapy for myeloproliferative neoplasms: when, which agent, and how?, Blood, 124, 3529, 10.1182/blood-2014-05-577635 Chott, 1990, Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis, Br J Haematol, 74, 10, 10.1111/j.1365-2141.1990.tb02531.x Radin, 2003, Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group, Cancer, 98, 100, 10.1002/cncr.11486 Cervantes, 1993, Alpha interferon treatment of idiopathic myelofibrosis, Med Clin (Barc), 101, 498 Schmitt, 2000, Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis, Blood, 96, 1342, 10.1182/blood.V96.4.1342 Centurione, 2004, Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice, Blood, 104, 3573, 10.1182/blood-2004-01-0193 Wen, 2011, Normal and malignant megakaryopoiesis, Expert Rev Mol Med, 13, e32, 10.1017/S1462399411002043 Gewirtz, 1986, Human megakaryocytopoiesis, Semin Hematol, 23, 27 Mullally, 2013, Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera, Blood, 121, 3692, 10.1182/blood-2012-05-432989 Stein, 2013, Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms, J Interferon Cytokine Res, 33, 145, 10.1089/jir.2012.0120 Vazquez, 2015, B cells responses and cytokine production are regulated by their immune microenvironment, Cytokine, 74, 318, 10.1016/j.cyto.2015.02.007 Tefferi, 2011, Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independ- ently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study, J Clin Oncol, 29, 1356, 10.1200/JCO.2010.32.9490 Kleppe, 2015, JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response, Cancer Discov, 5, 316, 10.1158/2159-8290.CD-14-0736 Tefferi, 2014, CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons, Leukemia, 28, 1472, 10.1038/leu.2014.3